LAURUSLABS logo

Laurus Labs Limited Stock Price

NSEI:LAURUSLABS Community·₹467.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

LAURUSLABS Share Price Performance

₹876.75
411.50 (88.45%)
14.5% undervalued intrinsic discount
₹1,025.00
Fair Value
₹876.75
411.50 (88.45%)
14.5% undervalued intrinsic discount
₹1,025.00
Fair Value
Price ₹876.75
AnalystHighTarget ₹1,025.00
AnalystConsensusTarget ₹694.85
AnalystLowTarget ₹293.00

LAURUSLABS Community Narratives

AnalystHighTarget·
Fair Value ₹1.03k 15.6% undervalued intrinsic discount

Digital Transformation And Affordable Generics Will Expand Global Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹694.85 24.5% overvalued intrinsic discount

Global Healthcare Growth Will Spur CDMO Expansion While Tempering Risks

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AnalystLowTarget·
Fair Value ₹303.09 185.4% overvalued intrinsic discount

Global Healthcare Regulation Will Squeeze Margins Amid Rising Costs

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent LAURUSLABS News & Updates

Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly

Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%

Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings

Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

May 19
Laurus Labs (NSE:LAURUSLABS) Has A Pretty Healthy Balance Sheet

Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27
Laurus Labs Limited Just Recorded A 7.2% EPS Beat: Here's What Analysts Are Forecasting Next

Laurus Labs Limited Key Details

₹59.3b

Revenue

₹26.9b

Cost of Revenue

₹32.4b

Gross Profit

₹27.3b

Other Expenses

₹5.1b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 23, 2025
Earnings per share (EPS)
9.43
Gross Margin
54.64%
Net Profit Margin
8.58%
Debt/Equity Ratio
60.0%

Laurus Labs Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
2 Rewards

About LAURUSLABS

Founded
2005
Employees
6167
CEO
Satyanarayana Chava
WebsiteView website
www.lauruslabs.com

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Indian Market Performance

  • 7 Days: 1.1%
  • 3 Months: -0.1%
  • 1 Year: -4.4%
  • Year to Date: 1.3%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 4.3%. In contrast, the market has seen a decline of 4.4% over the last 12 months. Earnings are forecast to grow by 16% annually. Market details ›